ScholarIQanswers from OpenAlex & ORCID
Hiroaki Nagano
ResearcherPublications, citations & collaboration network
Hiroaki Nagano is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hiroaki Nagano have?
ScholarIQindexed works
Hiroaki Nagano has 767 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hiroaki Nagano have?
ScholarIQcitation count
Hiroaki Nagano has 18,676 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hiroaki Nagano?
ScholarIQh-index
Hiroaki Nagano has an h-index of 70 in OpenAlex.
What is the i10-index of Hiroaki Nagano?
ScholarIQi10-index
Hiroaki Nagano has an i10-index of 309 in OpenAlex.
What is the ORCID of Hiroaki Nagano?
ScholarIQorcid
The ORCID for Hiroaki Nagano is on the source record.
What is the OpenAlex record for Hiroaki Nagano?
ScholarIQopenalex
The OpenAlex for Hiroaki Nagano is on the source record.
What are the most-cited papers on Hiroaki Nagano?
ScholarIQmost cited works
Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs
Norikatsu Miyoshi, Hideshi Ishii, Hiroaki Nagano, Naotsugu Haraguchi, Dyah Laksmi Dewi, Yoshihiro Kano, Shinpei Nishikawa, Masahiro Tanemura, Koshi Mimori, Fumiaki Tanaka, Toshiyuki Saito, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Hirofumi Yamamoto, Mitsugu Sekimoto, Yuichiro� Doki, Masaki Mori
CD13 is a therapeutic target in human liver cancer stem cells
Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Masahisa Ohkuma, Ho Min Kim, Hirofumi Akita, Daisuke Takiuchi, Hisanori Hatano, Hiroaki Nagano, Graham F. Barnard, Yuichiro� Doki, Masaki Mori
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma
Yoshito Tomimaru, Hidetoshi Eguchi, Hiroaki Nagano, Hiroshi Wada, Shogo Kobayashi, Shigeru Marubashi, Masahiro Tanemura, Akira Tomokuni, Ichiro Takemasa, Koji Umeshita, Tatsuya Kanto, Yuichiro� Doki, Masaki Mori
Defined factors induce reprogramming of gastrointestinal cancer cells
Norikatsu Miyoshi, Hideshi Ishii, Ken-ichi Nagai, Hiromitsu Hoshino, Koshi Mimori, Fumiaki Tanaka, Hiroaki Nagano, Mitsugu Sekimoto, Yuichiro� Doki, Masaki Mori
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, Hiroaki Yanagimoto, Soichiro Morinaga, Shogo Kobayashi, Kazuaki Shimada, Yu Takahashi, Toshio Nakagohri, Kunihito Gotoh, Ken Kamata, Yasuhiro Shimizu, Makoto Ueno, Hiroshi Ishii, Takuji Okusaka, Junji Furuse, Keiya Okamura, Yasuyuki Kawamoto, Akio Katanuma, Michiaki Unno, Hirofumi Shirakawa, Hironori Yamaguchi, Amane Takahashi, Masafumi Ikeda, Hiroo Yanagibashi, Naoya Kato, Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori